Bedrijfsoverzicht
SeaStar Medical Holding Corporation is a commercial-stage medical device enterprise focused on developing a proprietary platform therapy designed to mitigate the consequences of hyperinflammation affecting vital organs within the United States market. The organization operates within the healthcare sector, specifically targeting the biotechnology industry, which implies a focus on the development and commercialization of biological technologies and medical devices to address unmet medical needs. The company currently maintains a market capitalization of $14.82M, generates annual revenue of $1.23M, and employs a workforce of 17 individuals to execute its strategic initiatives. These valuation and revenue figures indicate that SeaStar Medical is a micro-cap entity with limited operational scale, reflecting its stage as a specialized developer rather than a large-cap market leader with diversified product lines.
Financiële gezondheid
The company reported revenue of $1.23M over the trailing twelve months, accompanied by a net income of $-12,150,000 and an EBITDA metric that is not available for calculation. The significant disparity between the positive revenue figure of $1.23M and the substantial net loss of $-12,150,000 reveals a cost structure where operating expenses and research and development costs heavily outweigh current revenue generation, a common characteristic in early-stage biotechnology firms. Free cash flow stands at $-9,391,750, indicating that the company is burning through cash reserves to fund its operations and development efforts rather than generating cash from its current business activities. Gross margin is reported at 95.7%, suggesting high pricing power or low direct production costs relative to revenue, whereas the operating margin is -718.1% and the profit margin is 0.0%, highlighting severe operational inefficiencies or high overhead relative to sales volume. In terms of liquidity and leverage, the company holds $11.98M in cash against $525,000 in debt, resulting in a debt-to-equity ratio of 5.04, which suggests a highly leveraged balance sheet relative to equity but provides a substantial cash buffer against obligations. The current ratio is 3.63, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities. Return on equity is -295.2% and return on assets is -80.9%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and the asset base, reflecting the high-risk nature of the current business model.
Waarderingsbeoordeling
Trailing P/E ratio is not available due to the lack of positive earnings, while the forward P/E is listed as -1.44, implying that the market is pricing in expectations of future profitability that have not yet materialized in historical data. The price-to-book ratio is 1.37, indicating that the stock is trading at a premium of 37% above its book value, which can reflect market optimism regarding future asset appreciation or intangible value despite current losses. Price-to-sales ratio stands at 12.01 and EV/EBITDA is not available; these alternative valuation metrics suggest that investors are willing to pay a significant multiple of sales for the company's revenue stream, prioritizing potential future growth over current profitability. The 52-week high is $13.50 and the 52-week low is $2.07, providing a trading range within which the stock's price has fluctuated over the past year. Without a specific current share price provided in the facts, the absolute percentage position relative to the high and low cannot be calculated, but the wide range of $11.43 between the high and low demonstrates significant price volatility. Beta is -1.19, a negative value that indicates the stock price moves inversely to the broader market, exhibiting volatility characteristics that are highly unusual for a standard equity security and suggests extreme sensitivity to market movements or specific sector-specific factors.
Growth & Income
Revenue growth year-over-year is 526.9%, while earnings growth year-over-year is not available; this divergence implies that the company is experiencing rapid top-line expansion but has not yet achieved consistent profitability to support meaningful earnings growth calculations. Since the company does not pay dividends, the dividend yield is not available and the payout ratio is 0.0%, indicating that the firm retains all of its earnings, or rather its losses, to reinvest into research and development and operational scaling rather than distributing income to shareholders. The overall growth and income profile is characterized by explosive revenue expansion supported by a cash-rich balance sheet, yet tempered by a lack of profitability and negative returns on capital that define the current stage of the biotechnology lifecycle.